



Contents lists available at ScienceDirect

Current Therapeutic Research

journal homepage: www.elsevier.com/locate/curtheres

Editorial: Publishing in 2023 and Beyond

I am excited to introduce myself as the new editor in chief of *Current Therapeutic Research* (CTR). I became involved in CTR as a reviewer and board member in 2014. I am thrilled to be taking on the role of editor in chief for CTR and to be involved with a journal that is open access and peer-reviewed. CTR focuses on research covering the entire spectrum of therapeutics, from medications to interventions and from discoveries to applications. Before expanding, I would like to recognize Dr Philip Walson for his long service as CTR's editor in chief. It will be hard to follow in the footsteps of someone who invested so much in CTR over the years and grew the Journal with his tireless efforts. Finally, thank you, Dr Walson, for staying involved as editor in chief emeritus.

Since undertaking my PhD, I have been interested in participating in the process of scientific publishing. As my career has evolved and as I have moved countries and institutions, I have seen the expectations and areas of scientific publishing change. I often hear the phrase “publish or perish” in different fields of science, and this can put unnecessary pressure on researchers. Today, many investigators are also concerned about finding a journal in which to publish and dealing with issues such as cost, access, time to publication, and obtaining sound and robust peer review.

Since undertaking my first review of a manuscript and receiving reviewer comments on my own manuscripts, I have built an understanding and appreciation for the process. I have held positions such as reviewer, executive editor, and senior editor for the *British Journal of Clinical Pharmacology*. In addition, I have held multiple roles within *BMC Pharmacology and Toxicology*, including section editor for clinical pharmacology, associate editor, and senior editorial board member. I also serve as the specialty co-chief editor for *Frontiers in Pharmacology: Obstetric and Pediatric Pharmacology*. Over the years, as my roles across scientific journals have changed, my outlook on the scientific publishing industry has fundamentally altered.

My overall goal is to help publish manuscripts in CTR and to improve the quality, impartiality, and openness of the peer review process. I would also like to ease authors' disappointment after reading comments that are not helpful or otherwise counterproductive to helping them publish their research. This can be a common occurrence for investigators. In all my years working either as a reviewer or in an editorial role, I have worked tirelessly to make the peer review process more rigorous, objective, and open. A close working relationship among editors, authors, and reviewers is key to successfully facilitating peer review.

The CTR Team

Our team includes our editorial advisory board and our long-term editors, whom I would like to thank for their continued commitment to the Journal. We will also have new, incoming editors excited to help the Journal grow and achieve its mission. In addition, we have a truly global editorial board with members who hail from varying countries or geographic regions.

We are supported through Elsevier by an amazing group, including Scott Whitener, senior publisher; Judy Pachella, managing editor; and Miodrag (Mio) Mitrić, PharmD, PhD, scientific editor, Elsevier, Health & Medical Sciences, STM Journals.

I would also like to acknowledge all those who agree to review manuscripts. I know being inundated with requests to review can cause fatigue. Many are still recovering from the pandemic, and time is precious. However, we could not do this without you; we could not provide the high standards, objectivity, and consistency of the peer-review process without your time and effort.

Growing Our Scientific Footprint

The traditional peer-review process has undergone many fascinating and highly beneficial modifications in recent years due to the rapid evolution of scientific publishing. We believe that peer review of scientific articles is an essential component of the scientific publishing process for ensuring the highest standards of methodological rigor; suitable scholarship; and professional, scientific communication. Since taking over in early 2023, with the input of the editorial board and Journal support team, we have updated and expanded the aims and scope of CTR. These can be found on the Journal web page: <https://www.elsevier.com/journals/current-therapeutic-research/0011-393X/guide-for-authors>.

The updated aims and scope emphasize studies of specific topics such as pediatric clinical trials and pediatric and maternal–fetal pharmacology and toxicology. In addition to preclinical and clinical investigations, research may include *in vitro* and *in vivo* techniques. Additionally, CTR will continue to promote inclusion and diversity by accepting submissions from all over the world, regardless of whether they pertain to an international or a country-specific audience (eg, a specific patient population).

CTR will keep growing as a multidisciplinary, international, peer-reviewed, open access scientific journal concerned with multiple facets of medicine, including the search for new treatments and their implementation. Researchers and health care practitioners based in various areas worldwide—from bench to

bedside—want access the latest developments in their fields. CTR's mission will continue to improve health care by publishing high-quality, rigorous, and ethically sound original research. This includes both positive and negative findings. Editorials, letters to the editor, research letters, brief papers, case reports, and meta-analyses are all encouraged. CTR is listed in all the major biological abstracting databases (eg, PubMed/Medline, Clarivate, and Scopus) that index published articles.

If you are interested in submitting an article to CTR but are unsure if it is a good fit, please contact us for feedback! If you want to create a research themed issue, please contact us and we will provide guidance! E-mail CurrTherRes@Elsevier.com and please consider submitting your manuscript at <https://www.editorialmanager.com/curtherres>

Social Media

The widespread use of social media has created new opportunities for disseminating scientific knowledge, promoting scientific activity, and accessing scientific knowledge. As a member of the scientific community, CTR is committed to optimizing these channels to effectively promote and disseminate your research to a wide audience. Please consider following our Twitter and LinkedIn pages:

Twitter: [Current Therapeutic Research \(@ctrjournal\)/Twitter](https://twitter.com/ctrjournal)

LinkedIn page: <https://www.linkedin.com/company/current-therapeutic-research/>

We will regularly post information related to recently accepted manuscripts, and if you want to keep promoting your work after it has been published, feel free to follow, share, and tag us.

Future

A journal only exists thanks to researchers' contributions, the journal's team, and the global scientific public it serves because of the generous time given by editors and reviewers. We depend on the support and interest of various scientific groups; therefore, we rely on your participation.

Moving forward, I will provide updates in future editorials regarding innovative and new initiatives. I look forward to reading your amazing research.

Catherine M. Sherwin, PhD*

*Division of Clinical Pharmacology, Department of Pediatrics,
University of Utah School of Medicine, Salt Lake City, Utah
Department of Experimental and Clinical Pharmacology, College of
Pharmacy, University of Minnesota, Minneapolis, Minnesota
Department of Pediatrics, Wright State University, Boonshoft School
of Medicine, Dayton Children's Hospital, Dayton, Ohio*

*Address correspondence to: Catherine M Sherwin, PhD,
Department of Pediatrics, Wright State University Boonshoft
School of Medicine/Dayton Children's Hospital, One Children's
Plaza, Dayton, OH, 45404-1815.

E-mail address: Catherine.sherwin85@gmail.com